問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



National Taiwan University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 1,343

    Total Beds

  • 801

    Total Doctors

  • n123987ctc@gmail.com
  • Hsin-Pin Tu
  • 06-2353535#4691
  • 704Tainan CityTainan NorthNo.138,Sheng Li Road,Tainan, Taiwan

Recruiting Trial

769Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1621Cases

2012-06-15 - 2013-06-15

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2018-01-01 - 2022-12-31

Phase III

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

  • Condition/Disease

    HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

  • Test Drug

    Tesetaxel

Participate Sites
7Sites

Terminated7Sites

趙大中
Taipei Veterans General Hospital

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

2017-03-01 - 2019-12-31

Phase III

A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer

  • Condition/Disease

    Advanced or Metastatic Gastric Cancer

  • Test Drug

    Apatinib

Participate Sites
10Sites

Terminated8Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2016-08-31 - 2018-12-31

Phase II

Multi-center, randomized, vehicle-controlled, investigator-blinded, parallel groups study to evaluate the efficacy and safety of NP000888 in subjects with plaque and nail psoriasis

  • Condition/Disease

    Psoriasis or nail psoriasis

  • Test Drug

    NP000888

Participate Sites
11Sites

Terminated11Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2019-08-07 - 2023-04-30

Phase III

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial

  • Condition/Disease

    Cholangiocarcinoma

  • Test Drug

    Infigratinib(BGJ398)

Participate Sites
8Sites

Recruiting8Sites

2014-05-20 - 2018-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2019-06-01 - 2023-02-09

Phase III

A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB12 (proposed eculizumab biosimilar) and Soliris®; in Subjects with Paroxysmal Nocturnal Haemoglobinuria

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria

  • Test Drug

    eculizumab (SB12 or EU sourced Soliris)

Participate Sites
3Sites

Recruiting3Sites

2020-01-31 - 2023-10-03

Phase II/III

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Test Drug

    GSK3359609

Participate Sites
7Sites

Recruiting7Sites

2016-05-10 - 2022-05-31

Phase III

A phase 3, randomized, double-blind, placebo-controlled study to compare efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in subjects with acute myeloid leukemia in complete remission.

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Oral Azacitidine (CC-486)

Participate Sites
6Sites

Terminated5Sites

2015-12-01 - 2020-04-30

Phase III

A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF/ Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

  • Condition/Disease

    Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

  • Test Drug

    Pexastimogene Devacirepvec (Pexa Vec)

Participate Sites
6Sites

Terminated6Sites

1 120 121 122 123 124 163
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB